NAE inhibitor MLN4924 effectively suppresses Coxsackievirus B3 replication.
Li Siwei, Wei Jianwei, Dong Yanyan, Luan Tian, Feng Danxiang, Wang Xuexuan, Wang Ziyuan, Zhao Yitong, Yang Bochao, Wang Yao, Lin Lexun, Zhong Zhaohua, Zhao Wenran
Abstract
Myocarditis, the inflammatory disease of the myocardium, is one of the leading causes of dilated cardiomyopathy and sudden cardiac death. Coxsackievirus B (CVB) is one of the common pathogens of myocarditis and cardiomyopathy. In spite of the high prevalence of CVB infection, effective antiviral therapy is lacking, primarily due to that there is no approved antiviral drug available. In the previous study, we demonstrated that the neddylation of 3Dpol, the RNA-dependent RNA polymerase, promotes CVB replication. Therefore, we propose that targeting neddylation might be a therapeutic strategy against CVB infection. Here we studied the antiviral effect of MLN4924, the selective inhibitor of neddylation. We show that MLN4924 exerted potent antiviral effect with negligible cytotoxicity when applied at the early stage of CVB3 infection. MLN4924 treatment significantly inhibited viral replication both in vitro and in the myocardium of CVB3-infected mice. The myocardial damage and inflammatory response induced by CVB3 were significantly alleviated. We show that MLN4924 suppressed the neddylation of 3Dpol, leading to its upregulated degradation. Moreover, MLN4924 upregulated nuclear factor erythroid 2-related factor 2 (NRF2) through inhibiting its ubiquitination and proteasomal degradation, while CVB3 infection clearly enhanced NRF2 ubiquitination. Taken together, we conclude that MLN4924 exerts anti-CVB effect both in vitro and in vivo. In addition to inhibiting the neddylation of viral 3Dpol, upregulated NRF2 also contributes to the antiviral activity of MLN4924. This study demonstrated that targeting neddylation can be a potential antiviral strategy for the treatment of CVB infection.
Key Findings
- MLN4924, a selective inhibitor of neddylation, effectively suppresses Coxsackievirus B3 (CVB3) replication with negligible cytotoxicity.
- MLN4924 inhibits the neddylation of the viral RNA-dependent RNA polymerase 3Dpol, leading to its increased degradation and reduced viral replication.
- MLN4924 upregulates NRF2 by inhibiting its ubiquitination and proteasomal degradation, contributing to its antiviral effects against CVB3.
Clinical Significance
MLN4924 shows promise as a potential antiviral therapeutic agent for treating Coxsackievirus B3 infections by targeting viral protein neddylation and enhancing NRF2-mediated antiviral responses.
Citation
Li Siwei, Wei Jianwei, Dong Yanyanet al.. NAE inhibitor MLN4924 effectively suppresses Coxsackievirus B3 replication. Microbial pathogenesis. 2026-Jun-19.